Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2020-11-06 Capital/Financing Update
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Vaccibody announces the closing of the worldwide license and collaboration agreement with Genentech
Capital/Financing Update Classification · 95% confidence The document is an announcement titled "Vaccibody announces the closing of the worldwide license and collaboration agreement with Genentech." It details the finalization of a major business transaction, including financial terms (USD 200 million upfront payment, potential milestones up to USD 515 million), and regulatory clearance (HSR Act expiration). This type of announcement, concerning fundraising, financing activities, or significant corporate agreements/partnerships, aligns best with the 'Capital/Financing Update' category, as it involves a large cash inflow and strategic collaboration. It is not an Earnings Release (ER) as it focuses on a deal closing, not periodic financial results. It is not a standard Regulatory Filing (RNS) because it fits the specific definition of CAP better. It is not a Merger/Acquisition (TAR) as it is a license and collaboration agreement, not a takeover bid.
2020-11-06 English
Vaccibody announces the closing of the worldwide license and collaboration agreement with Genentech
Capital/Financing Update Classification · 95% confidence The document announces the closing of a major 'worldwide license and collaboration agreement' between Vaccibody and Genentech, detailing financial terms (upfront payments, milestones, royalties) and the progression of a product candidate into clinical trials. This type of announcement, detailing significant corporate financing, partnership structuring, and future development costs, fits best under 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it specifically concerns a major capital/licensing transaction.
2020-11-06 English
MANDATORY NOTIFICATION OF TRADE - PRIMARY INSIDER
Director's Dealing Classification · 100% confidence The document is titled "MANDATORY NOTIFICATION OF TRADE - PRIMARY INSIDER" and details specific share purchases and sales conducted by a board member (Christian Åbyholm) and entities he represents (Caaby AS, Andenaesgruppen, Norda ASA) in Vaccibody AS. This directly corresponds to the definition of Director's Dealing, which covers reports of personal share transactions by company directors and executives (insider trades). The appropriate code is DIRS.
2020-10-22 English
Share capital increase from exercise of warrants
Share Issue/Capital Change Classification · 98% confidence The document explicitly states the subject is a "Share capital increase from exercise of warrants." It details the resulting change in share capital (from NOK 2,836,276.80 to NOK 2,845,376.80) and the increase in the number of outstanding shares (from 283,627,680 to 284,537,680). This directly relates to changes in the company's capital structure due to the issuance of new shares following warrant exercise. This aligns perfectly with the definition for Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA). Since it details the resulting capital change and share count, SHA is the most precise fit, although CAP is also relevant. I will select SHA as it specifically addresses the share count change.
2020-10-21 English
MANDATORY NOTIFICATION OF TRADE - PRIMARY INSIDER
Director's Dealing Classification · 100% confidence The document is titled "MANDATORY NOTIFICATION OF TRADE - PRIMARY INSIDER" and details share purchases made by a board member (Christian Åbyholm) and entities he represents (Caaby AS, Andenaesgruppen, Christiania Skibs AS, Norda ASA). This directly corresponds to the definition of Director's Dealing, which covers reports of personal share transactions by company directors and executives (insider trades). The appropriate code is DIRS.
2020-10-07 English
Vaccibody AS Lists on Oslo Stock Exchange’s Merkur Market
Share Issue/Capital Change Classification · 95% confidence The document announces that Vaccibody AS's shares have been admitted to trading on the Oslo Stock Exchange's Merkur Market, effective October 7, 2020. This announcement details the listing process, ticker symbol, outstanding shares, and ISIN. This type of corporate action, related to stock exchange listing or trading status, does not fit neatly into standard financial reporting categories like 10-K, ER, or IR. It is a specific corporate event announcement. Since it is not a Director's Dealing (DIRS), Capital Change (SHA), or Delisting (DLST), and it is a formal announcement regarding market access, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory/exchange announcement, or potentially a Capital/Financing Update (CAP) if the listing is considered a primary financing event, but RNS is a better fit for general exchange admission notices not covered elsewhere.
2020-10-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.